Dementia Rating Scale Score Research Articles

Time Dependency of Cognitive Recovery with Cobalamin Replacement: Report or a Pilot Study

To examine the effects of cobalamin repletion on cognition in elderly subjects with low serum cobalamin and evidence of cognitive dysfunction. Time series data collected in an open trial of parenteral cobalamin therapy. Outpatient geriatric assessment centers, inpatient geropsychiatry unit, and tertiary care university hospital. Twenty-two subjects with low serum cobalamin (less than 150 pmol/L) and evidence of cognitive dysfunction were entered consecutively over an 8-month period of time. Eighteen subjects completed the study. Subjects received 1000 micrograms of cyanocobalamin intramuscularly daily for 1 week, then weekly for 1 month, then monthly thereafter for a minimum of six months. OUTPATIENT MEASURE: The Mattis Dementia Rating Scale (DRS) was administered both before and at least 6 months after full cobalamin replacement therapy. The hypothesis that cognitive improvement was dependent on the duration of cognitive symptoms was formulated a posteriori. After a minimum of 6 months of cobalamin therapy, 11 of 18 patients showed cognitive improvement. There was a striking correlation between duration of cognitive symptoms and response to therapy. Patients symptomatic for less than 12 months gained an average of twenty points on the DRS (paired t test P = 0.0076), whereas patients symptomatic greater than 12 months lost an average of three points (paired t test P = .34). Two patients symptomatic for only 3 months normalized their DRS scores, gaining 31 and 28 points, respectively. There may be a time-limited window of opportunity for effective intervention in patients with cognitive dysfunction and low serum cobalamin.

Use of the dementia rating scale as a test for neuropsychological dysfunction in HIV-positive IV drug abusers

Intravenous drug abusers (IVDAs) represent an increasing proportion of the HIV epidemic. Forty-three IVDA's (22 HIV-negative, 21 HIV-positive) were studied using the Mattis Dementia Rating Scale (DRS). All subjects had used intravenous heroin, but reported that they were drug-free at the time of testing. HIV-positive subjects were predominantly symptomatic and were dichotomized into AIDS and non-AIDS groups. All subjects with abnormal DRS scores were HIV-positive (57% of all HIV-positives). All HIV-negative subjects had normal DRS scores while 43% of the positive group obtained such scores. The DRS reliably identifies neuropsychological impairment, and may be a useful screening tool in this population.

The Clinical Validity of the Mattis Dementia Rating Scale in Staging Alzheimer's Dementia

Considerable heterogeneity exists in the criteria used for the establishment of stages of impairment for patients with dementia. The valid distinction of stages is important both for clinical interpretation and the study of dementia. This study reports on the use of the Mattis Dementia Rating Scale (DRS) in staging dementia. Using a sample of 42 patients diagnosed with Alzheimer-type dementia, DRS performance and a rating of Instrumental Activities of Daily Living (IADL) were compared with clinical ratings of dementia severity. Total DRS score provides a clinically valid measure of stage of impairment and appeared to provide a better distinction among stages than IADL score. However, use of the IADL score in conjunction with total DRS may improve correspondence with clinical staging over use of the total DRS score alone. Normative data for the DRS are also provided.

Differentiation of Alzheimer's Disease and Huntington's Disease With the Dementia Rating Scale

Patients with dementia of the Alzheimer type (DAT) and Huntington's disease (HD) were assessed with the Dementia Rating Scale, a brief mental status examination that provides a global dementia score and subtest scores for attention, initiation, construction, conceptualization, and memory capacities. Although the patients with DAT and the patients with HD were precisely matched in terms of total Dementia Rating Scale score, different subtest score profiles emerged. Patients with DAT were more impaired than patients with HD on the Memory subtest, whereas patients with HD were more impaired than patients with DAT on the initiation subtest. These results are indicative of qualitative differences in the cognitive impairment of the two disorders and demonstrate that such differences can be elucidated with brief mental status examinations.

The clinical utility of the Dementia Rating Scale for assessing Alzheimer patients

Community residing patients with mild ( n = 18) or moderately severe ( n = 16) Alzheimer's disease and controls ( n = 23) were given Mattis' Dementia Rating Scale (DRS) and a brief measure of confrontation naming selected from the Boston Naming Test (BNT). The DRS was shown to be a reliable and clinically useful measure of mental status in patients with Alzheimer's disease. The DRS subscales and the BNT had excellent internal consistency reliabilities and the total DRS score (TDRS) was shown to be generally unrelated to gender and education. Among the dementia patients, performance on the TDRS was significantly associated with functional competence. The two dementia samples had similar profiles on the DRS and BNT, with the mild subjects performing significantly better than the moderately severe subjects on each measure. Extending the range of DRS subscales would improve this measure's utility as an evaluation instrument.